AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04267627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)
Description: Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
Study NCT00803478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Study NCT03475030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-filled medication trays
Study NCT03475030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automated medication reminders
Study NCT02260830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Study NCT01273779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin alfa
Description: 15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
Study NCT01273779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
Study NCT01453465 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03735030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human hCG 10'000 IU
Description: A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
Study NCT03735030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant hCG 6'500 IU
Description: A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.
Study NCT02092805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)
Study NCT02092805 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).
Study NCT03254771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
Study NCT04315662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle power training with velocity loss (VL) of 10%
Description: Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.
Study NCT04315662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle power training with velocity loss (VL) of 30%
Description: Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
Study NCT00830700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CATMH intervention
Description: This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
Study NCT04709926 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Paramedics will complete a 5 minute survey that is asking for their opinions on why they did or did not take part in the PRESTO training package and also why they think paramedics might not engage with research training in general.
Study NCT04709926 — intervention group
Intervention type: OTHER
Intervention: Interview (optional)
Description: Paramedics will also be given the option to participate in a 1hr interview to explore the questions asked in the survey in more detail.
Study NCT01789905 — intervention group
Intervention type: DRUG
Intervention: Tigecycline (Tygacil)
Description: Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Study NCT03322111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measurement of the cyclofusion
Description: Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
Study NCT02287675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoseek
Description: Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
Study NCT02287675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur Colloid
Description: Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
Study NCT02068105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet
Study NCT06009185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
Study NCT01947907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001
Description: Once weekly subcutaneous injection
Study NCT01947907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Once daily subcutaneous injection of human Growth Hormone
Study NCT02866851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring by Web-application
Description: Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
Study NCT02785237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coroflex® ISAR Drug-eluting stent
Description: Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
Study NCT02785237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultimaster® Drug-eluting stent
Description: Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
Study NCT01633593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg PO a day, during 2 weeks
Study NCT00868790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
Study NCT02068105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablet
Study NCT04331665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
Study NCT02575222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
Study NCT03525860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The subject is placed in the selected position (lying down or sitting), based on their comfort level. The areas to be needled are prepped with an alcohol swab. Mandatory standards and safety guidelines for acupuncture will be followed.~The acupuncture treatment protocol will be based on Traditional Chinese Medicine (TCM) theory. The TCM treatment strategy is designed to Benefit the Heart, Tonify Heart Qi and Blood, Calm and Sedate Cardiac Excitability and Regulate the Qi. Current literature supports the use of selected acupuncture points as possibly beneficial in regulating the autonomic nervous system, modulating Heart Rate Variability (HRV), relieving chest pain, and reducing arrhythmias.~11 sterile, single use, disposable needles will be placed one by one until all needles are in place.~Needles remain in place for additional 20 minutes or so as the patient remains in the selected position~.
Study NCT02897375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02897375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02897375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT03429725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (statements writing)
Description: Participants to write statements describing themselves or their similarities to their community.
Study NCT03429725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (circling)
Description: Participants to circle either pronouns denoting themselves or pronouns denoting others.
Study NCT03429725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (Sumarian Warrior)
Description: Participants read a passage which described the factors that led to his success in a war.
Study NCT03429725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (all)
Description: Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.
Study NCT04601792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study NCT04601792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study NCT04601792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of TCM, the modification of Bronchiectasis Stabilization Decoction (Rhizoma Fagopyri Cymosi 30g, Radix Lithospermi 15g, Radix Ophiopogonis 15g, Poria cocos 15g, Radix Astragali 20g, Rhizoma Bletillae 10g, Platycodon grandiflorum 10g, Semen Coicis 30g) based on syndrome differentiation. For example, for patients with qi and yin deficiency syndrome, the investigators added Adenophora Root, Radix Glehniae and Radix Rehmanniae Recens etc. For patients with phlegm-heat syndrome, the investigators added Radix Scutellariae and Viola Yedoensis etc. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study NCT04601792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Study NCT04601792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Study NCT01633593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 5 mg PO a day, during 2 weeks
Study NCT00868790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
Study NCT00868790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
Study NCT04601792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tested drug minus heat-clearing herbs
Description: It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
Study NCT04601792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tested drug minus heat-clearing herbs
Description: It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
Study NCT02853682 — intervention group
Intervention type: BIOLOGICAL
Intervention: plasma
Description: assesment of glycocalyx protein
Study NCT02045550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prospan Syrup
Description: 2.5 ml twice daily for 4 weeks
Study NCT01042886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PILI 'Ohana Lifestyle Program
Description: 9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
Study NCT01042886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Maintenance Program
Description: 9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
Study NCT02406898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: morcellator uterine system (MH)Karl Storz, Tuttligen- Germany
Study NCT02406898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: morcellator uterine system (MH)Karl Storz, Tuttligen- Germany
Study NCT04189250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments
Description: The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
Study NCT04189250 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments
Description: The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
Study NCT01719731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: This group will receive the psychoeducation
Study NCT01719731 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Education
Description: This group will not receive the psychoeducation
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was provided as a sterile solution for injection.
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as a sterile solution for injection.
Study NCT00550537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/m2 given through a vein for every 3 weeks
Study NCT00550537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC = 6 given through a vein on day 1 of each cycle.
Study NCT00550537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150 mg taken by mouth daily
Study NCT00550537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m2 given through a vein on day 1 of each cycle.
Study NCT00550537 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Blood and tissue collection.
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Study NCT00550537 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Blood and tissue collection.
Study NCT00564993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamin
Description: 10\&20 µg/kg/min
Study NCT01849757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: prime crystalloid
Description: used for priming the CPB circuit
Study NCT01849757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin
Description: Used as a constituent for priming the CPB circuit
Study NCT01849757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voluven
Description: Used as a constituent for priming the CPB circuit
Study NCT01834404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine-Topiramate ER
Description: The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
Study NCT01834404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills matched the study drug in appearance for the 2 dose levels.
Study NCT03827161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine
Description: Given PO